➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Baxter
McKinsey
Merck
Express Scripts

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

ZINBRYTA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ZINBRYTA
Recent Litigation for ZINBRYTA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
PFIZER INC. v. ZYDUS PHARMACEUTICALS (USA) INC.2020-02-28
Pfizer Inc. v. Ajanta Pharma Ltd.2019-03-15
Pfizer Inc. v. Teva Pharmaceuticals USA, Inc.2018-12-07

See all ZINBRYTA litigation

PTAB Litigation
PetitionerDate
2017-12-20
2012-09-25

See all ZINBRYTA litigation

Patent Text Search: US Patents for ZINBRYTA

These patents were identified by searching patent claims

Supplementary Protection Certificates for ZINBRYTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300646 Netherlands   Start Trial PRODUCT NAME: OCLACITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER OCLACITINIB MALEAAT; REGISTRATION NO/DATE: EU/2/13/154/001-006 20130912
1690055-7 Sweden   Start Trial PRODUCT NAME: DACLIZUMAB OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOF; REG. NO/DATE: EU/1/16/1107 20160705
2016/053 Ireland   Start Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
132016000123368 Italy   Start Trial PRODUCT NAME: DACLIZUMAB(ZINBRYTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1107, 20160705
C01235830/01 Switzerland   Start Trial PRODUCT NAME: TOFACITINIB; REGISTRATION NO/DATE: SWISSMEDIC 62630 12.07.2013
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Mallinckrodt
Johnson and Johnson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.